Burden of illness in idiopathic pulmonary fibrosis.
Burden of illness in idiopathic pulmonary fibrosis.
复制标题
DOI：
10.3111/13696998.2012.680553
复制
发表时间：
2012-01-01
影响因子：
2.4
通讯作者：
Hunsche, Elke
中科院分区：
文献类型：
--
作者：
Collard, Harold R;Ward, Alex J;Hunsche, Elke
背景技术背景：特发性肺纤维化是一种危及生命的疾病，有关其对医疗保健利用和相关费用的影响的数据很少。本研究的目的是描述疾病的负担（合并症，医疗资源利用，和相关费用）在特发性肺纤维化患者。方法：两个队列（特发性肺纤维化患者和匹配的对照组）回顾性确定从美国索赔数据库2001年1月1日至2008年9月30日。特发性肺纤维化病例的定义为年龄≥ 55岁，有两个或多个特发性纤维化肺泡炎（ICD-9 516.3）代码的索赔，或一个ICD 516.3索赔和一个炎症后肺纤维化（ICD-9 515）代码的后续索赔。预先选定的合并症，医疗资源利用（医院，门诊，药物），和直接医疗costs.RESULTS的患病率和发病率进行了评估，在每个coherent.A共9286例特发性肺纤维化患者被确定。与年龄和性别匹配的对照组相比，这些患者合并肺动脉高压和肺气肿的风险显著增加。全因住院率（0.5/人年）和全因门诊就诊率（28.0/人年）均为对照组的2倍。特发性肺纤维化患者的总直接成本为26，378美元/人年;对照组的增量成本为12，124美元（2008年值）。结论：与对照组相比，特发性肺纤维化患者的并发症、医疗资源利用和直接医疗成本增加。
BACKGROUND: Idiopathic pulmonary fibrosis is a life-threatening condition, and few data concerning the impact on healthcare utilization and associated costs are available. The objective of this study was to describe the burden of illness (comorbidity, healthcare resource utilization, and associated costs) in patients with idiopathic pulmonary fibrosis.METHODS: Two cohorts (patients with idiopathic pulmonary fibrosis and matched controls) were retrospectively identified from US claims databases between January 1, 2001 and September 30, 2008. Cases with idiopathic pulmonary fibrosis were defined by age of 55 years or older and either two or more claims with a code for idiopathic fibrosing alveolitis (ICD-9 516.3), or one claim with ICD 516.3 and a subsequent claim with a code for post-inflammatory pulmonary fibrosis (ICD-9 515). The prevalence and incidence of pre-selected comorbidities, healthcare resource utilization (hospital, outpatient, drugs), and direct medical costs were assessed in each cohort.RESULTS: A total of 9286 patients with idiopathic pulmonary fibrosis were identified. When compared with age- and gender-matched controls, these patients were at significantly increased risk for comorbidities including pulmonary hypertension and emphysema. The all-cause hospital admission rate (0.5 per person-year) and the all-cause outpatient visit rate (28.0 per person-year) were both 2-fold higher than in controls. Total direct costs for patients with idiopathic pulmonary fibrosis were $26,378 per person-year; the incremental costs over controls were $12,124 (2008 value).CONCLUSIONS: Patients with idiopathic pulmonary fibrosis experience increased comorbidity, healthcare resource utilization, and direct medical costs compared to controls.